A growing number of researchers believe the pharma industry has entered a new wave of innovation involving multispecific medicines. Among them is Ray Deshaies, a biochemist and cell biologist, who is the SVP of global research at Amgen.  In 2020, Deshaies wrote an article for Nature explaining why multispecific drugs may grant access to portions of the…